Skip to main content
TipRanks
Go Ultimate75% OFF

Fusion Antibodies Plc (FAB) Stock Statistics & Valuation Metrics

10 Followers

Total Valuation

Fusion Antibodies Plc has a market cap or net worth of GBX 5.32M. The enterprise value is GBX 13.92M.

Market Cap
GBX 5.32M
Enterprise Value
GBX 13.92M

Share Statistics

Fusion Antibodies Plc has 125,156,876 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
125,156,876
Owned by Insiders
4.55%
Owned by Institutions
―

Financial Efficiency

Fusion Antibodies Plc’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -99.85%.

Return on Equity (ROE)
-0.71
Return on Assets (ROA)
-0.42
Return on Invested Capital (ROIC)
-99.85%
Return on Capital Employed (ROCE)
-1.05
Revenue Per Employee
78.15K
Profits Per Employee
-42.56K
Employee Count
27
Asset Turnover
0.77
Inventory Turnover
2.78

Valuation Ratios

The current PE Ratio of Fusion Antibodies Plc is -4.29. Fusion Antibodies Plc’s PEG ratio is -0.05.

PE Ratio
-4.29
PS Ratio
2.52
PB Ratio
3.09
Price to FCF
-4.55
Price to Operating Cash Flow
-4.52
PEG Ratio
-0.05

Income Statement

In the last 12 months, Fusion Antibodies Plc had revenue of 2.11M and earned -1.15M in profits. Earnings per share was -0.01.

Revenue
2.11M
Gross Profit
1.10M
Operating Income
-1.98M
Pretax Income
-1.15M
Net Income
-1.15M
EBITDA
-1.85M
Earnings Per Share (EPS)
-0.01

Cash Flow

In the last 12 months, operating cash flow was -1.11M and capital expenditures -60,000, giving a free cash flow of -1.17M billion.

Operating Cash Flow
-1.11M
Free Cash Flow
-1.17M
Free Cash Flow per Share
-0.01

Dividends & Yields

Fusion Antibodies Plc pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-21.98%
Earnings Yield
-22.92%

Stock Price Statistics

Beta
-0.74
52-Week Price Change
-66.00%
50-Day Moving Average
8.59
200-Day Moving Average
11.51
Relative Strength Index (RSI)
19.91
Average Volume (3m)
627.91K

Important Dates

Fusion Antibodies Plc upcoming earnings date is Dec 07, 2026, TBA (Not Confirmed).

Last Earnings Date
Sep 14, 2026
Next Earnings Date
Dec 07, 2026
Ex-Dividend Date
―

Financial Position

Fusion Antibodies Plc as a current ratio of 2.82, with Debt / Equity ratio of 20.41%

Current Ratio
2.82
Quick Ratio
2.39
Debt to Market Cap
0.01
Net Debt to EBITDA
0.38
Interest Coverage Ratio
-99.05

Taxes

In the past 12 months, Fusion Antibodies Plc has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Fusion Antibodies Plc EV to EBITDA ratio is -3.06, with an EV/FCF ratio of -3.94.

EV to Sales
2.18
EV to EBITDA
-3.06
EV to Free Cash Flow
-3.94
EV to Operating Cash Flow
-4.15

Balance Sheet

Fusion Antibodies Plc has GBX 1.04M in cash and marketable securities with GBX 331.00K in debt, giving a net cash position of GBX 712.00K billion.

Cash & Marketable Securities
GBX 1.04M
Total Debt
GBX 331.00K
Net Cash
GBX 712.00K
Net Cash Per Share
GBX 0.01
Tangible Book Value Per Share
GBX 0.01

Margins

Gross margin is 52.32%, with operating margin of -95.02%, and net profit margin of -54.45%.

Gross Margin
52.32%
Operating Margin
-95.02%
Pretax Margin
-54.45%
Net Profit Margin
-54.45%
EBITDA Margin
-71.37%
EBIT Margin
-77.39%

Analyst Forecast

The average price target for Fusion Antibodies Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
7.38%
EPS Growth Forecast
44.13%

Scores

Smart Score
―
AI Score
43